Abstract
Compliance Aids have gained widespread use to assist patients in managing their medicines, with a view to addressing the issue of adherence. However, although patient outcomes may have been improved through better use of compliance aids, it has been highlighted that there are limited data on the stability of medicines, when removed from the original container and repackaged in a compliance aid. Exposure of medicines to heat, light, moisture and air (oxygen) may impact on both their chemical and physical stability, resulting in the potential for quality of the medicine and thus the safety for the patient being compromised. It is also uncertain whether the compliance aid can provide the same protection from these environmental conditions as the manufacturer’s packaging, even though the time frame for repackaging is only 28 days. This paper presents a comprehensive review and detailed discussion of the available literature on the stability implications of repackaging medicines into compliance aids. The importance of repackaging is thus highlighted by its ability to impact on therapeutic outcomes for patients.
Keywords: Dose Administration Aids, quality, repackaging, safety, stability, storage.
Current Drug Safety
Title:Evidence of Stability of Medicines Repackaged in Compliance Aids: A Review
Volume: 11 Issue: 1
Author(s): Alison Haywood and Beverley D. Glass
Affiliation:
Keywords: Dose Administration Aids, quality, repackaging, safety, stability, storage.
Abstract: Compliance Aids have gained widespread use to assist patients in managing their medicines, with a view to addressing the issue of adherence. However, although patient outcomes may have been improved through better use of compliance aids, it has been highlighted that there are limited data on the stability of medicines, when removed from the original container and repackaged in a compliance aid. Exposure of medicines to heat, light, moisture and air (oxygen) may impact on both their chemical and physical stability, resulting in the potential for quality of the medicine and thus the safety for the patient being compromised. It is also uncertain whether the compliance aid can provide the same protection from these environmental conditions as the manufacturer’s packaging, even though the time frame for repackaging is only 28 days. This paper presents a comprehensive review and detailed discussion of the available literature on the stability implications of repackaging medicines into compliance aids. The importance of repackaging is thus highlighted by its ability to impact on therapeutic outcomes for patients.
Export Options
About this article
Cite this article as:
Haywood Alison and Glass D. Beverley, Evidence of Stability of Medicines Repackaged in Compliance Aids: A Review, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666150928104931
DOI https://dx.doi.org/10.2174/1574886310666150928104931 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imaging Subclinical Atherosclerosis: Where Do We Stand?
Current Cardiology Reviews Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Structure and Function of Myelinated Nerve Fibers in the Rabbit Eye Following Ischemia/Reperfusion Injury
Current Neurovascular Research Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design The Role of Interleukin-18 in the Development and Progression of Atherosclerosis
Current Medicinal Chemistry Macrophage Differentiation to Foam Cells
Current Pharmaceutical Design Lifestyle Factors and Endothelial Function
Current Vascular Pharmacology Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Repair of Dilated Aortic Root and Sinotubular Junction Using a Stabilizer Ring
Recent Patents on Cardiovascular Drug Discovery Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis
Current Vascular Pharmacology Molecular Genetics of Abdominal Aortic Aneurysm: Therapeutic Implications
Current Pharmacogenomics and Personalized Medicine Radiolabeled Sugars Used for PET and SPECT Imaging
Current Radiopharmaceuticals Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets The Role of Vascular Cell Senescence in Atherosclerosis: Antisenescence as a Novel Therapeutic Strategy for Vascular Aging
Current Vascular Pharmacology Pleiotropic Effects of Statins: Stabilization of the Vulnerable Atherosclerotic Plaque?
Current Pharmaceutical Design A Novel Finding: Macrophages Involved in Inflammation Participate in Acute Aortic Dissection Complicated with Acute Lung Injury
Current Molecular Medicine Animal Models for Studying Neointima Formation
Current Vascular Pharmacology Functional Effects of Levosimendan in Rat Basilar Arteries In Vitro
Current Neurovascular Research The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection
Current Pharmaceutical Design Perinatal Brain Injury
Current Pediatric Reviews